Orthocell Ltd's (ASX:OCC) Paul Anderson discusses with Proactive positive nerve regeneration results one year on from a study testing its nerve repair candidate on quadriplegic patients. The regenerative medicine company conducted the first interim data readout of all patients in the CelGro® clinical trial 12 months after the study concluded. 25 out of 33, or 75.8%, of all nerve repairs that took place during the study resulted in functional recovery.
Orthocell thrilled with positive nerve regeneration results
